Edition:
United Kingdom

Allakos Inc (ALLK.OQ)

ALLK.OQ on NASDAQ Stock Exchange Global Select Market

42.18USD
19 Oct 2018
Change (% chg)

$-0.28 (-0.66%)
Prev Close
$42.46
Open
$42.32
Day's High
$42.32
Day's Low
$41.06
Volume
2,967
Avg. Vol
--
52-wk High
$49.00
52-wk Low
$26.00

Summary

Name Age Since Current Position

Christopher Bebbington

2017 President, Founder, Director

Robert Alexander

46 2017 Chief Executive Officer, Director

Nenad Tomasevic

2016 Co-Founder, Vice President - Research

Adam Tomasi

46 Chief Financial Officer, Chief Operating Officer

John McKearn

Director

Biographies

Name Description

Christopher Bebbington

Dr. Christopher Bebbington, Ph.D., is President, Founder, Director of Allakos Inc. He has more than 25 years experience in the biopharmaceutical industry. He held various scientific and leadership roles at Celltech Ltd, including Head of Mammalian Expression and Team leader in Immunomodulation. During this time, he developed expression systems for recombinant antibodies, including the GS-System™, currently used in the manufacture of several approved antibody products, and conducted research into T-cell activation and chimeric antigen receptors. He was Director of Molecular Immunology at Coulter Pharmaceutical Inc., Senior Director of Research at Corixa Corp. and led a team that transferred to Medarex Inc on the acquisition by Medarex of antibody-drug conjugate technology and assets from Corixa. In 2003, Dr Bebbington was a co-founder of Celscia Therapeutics, a therapeutic antibody development company which merged in 2004 to form KaloBios Pharmaceuticals Inc. At KaloBios he was Vice President of Research, leading a team that developed a novel antibody humanization technology, “Antibody Humaneering™”, outlicensed to multiple partners, and entered 4 antibodies into clinical trials. He co-founded Allakos in 2012. He has a Bachelor of Arts in Natural Science from the University of Oxford, U.K. and a Master of Arts and Doctor of Philosophy also from the University of Oxford.

Robert Alexander

Dr. Robert D. Alexander is Chief Executive Officer, Director of the Company. Dr Alexander has held leadership positions in biotechnology and has been involved in the formation and management of numerous biotechnology companies. Robert was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Robert was a Director at Alta Partners, a venture capital firm and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Robert was a Principal in MPM Capital’s BioEquities Fund. Robert joined MPM from Genentech, where he worked in the Business Development group. He holds a PhD in immunology from the University of North Carolina at Chapel Hill and a bachelor’s degree in zoology from Miami University of Ohio.

Nenad Tomasevic

Dr. Nenad Tomasevic, Ph.D. is Co-Founder, Vice President - Research of the Company. Dr Tomasevic is a co-founder of Allakos. He received a Bachelor of Science degree in Chemistry from the University of Belgrade in Yugoslavia and a Master of Science and Ph.D. in Biochemistry at the same university. He completed postdoctoral training at National Institutes of Health (NIDDK, Genetics and Biochemistry Branch) in Bethesda, Maryland in the laboratory of Dr. Brenda Peculis. During the training, he discovered 2 previously uncharacterized proteins. After that, he joined Cytokinetics leading a team that identified small molecule inhibitors of key players involved in actin dynamics i.e. cell motility. The data have been published in prestigious scientific journals. At Nuvelo, he led a protein biochemistry group that accomplished numerous preclinical studies on protein and antibody therapeutics. He was director of Protein biochemistry at KaloBios and his team supported preclinical and clinical activities for 3 clinical-stage antibodies. During this time, he was a team leader for an antibody program in allergy. He co-founded Allakos in 2012.

Adam Tomasi

Mr. Adam Tomasi is Chief Financial Officer, Chief Operating Officer of the Company. Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor relation functions through the company’s initial public offering and sale to AstraZeneca. Before joining ZS Pharma, Dr. Tomasi was a Principal at Alta Partners where he contributed to investments in ZS Pharma (acquired by AstraZeneca), Lumena Pharmaceuticals (acquired by Shire), Excaliard (acquired by Pfizer), ChemGenex (acquired by Cephalon), Achaogen, Immune Design and Allakos. Dr. Tomasi served as a drug discovery scientist with Gilead Sciences and Cytokinetics. He holds an M.B.A. from the Harvard-MIT Biomedical Enterprise Program, a bachelor’s degree in chemistry from the University of California, Berkeley and a Ph.D. in chemistry from the University of California, Irvine. Henrik Rasmussen MD, PhD Chief Medical Officer Christopher Bebbington DPhil Chief Scientific Officer

John McKearn

Dr. John P. McKearn Ph.D. is Director of Allakos Inc. He joined RiverVest in April 2008 as a Venture Partner and became a Managing Director in April 2011. He has over 25 years experience as a successful "drug hunter and developer" in both large and small biopharma, including a decade in small-cap and venture-backed companies. John serves on the board of Otonomy Inc., Lumena Pharmaceuticals, Inc., Allakos and ZS Pharma, all RiverVest Fund II portfolio companies. Prior to joining RiverVest, he was president and CEO of Kalypsys, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc. John holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease. John worked as a scientist with Searle / Pharmacia, from 1987-2003, including head of discovery research from 1997-2003. Through his efforts, John helped establish the groundwork for new studies that led to the commercialization of several major products, including DayPro, Arthrotec, and most notably, Celebrex, one of the leading pharmaceuticals to treat arthritis. Prior to 1987, John was a senior scientist at E.I. DuPont de Nemours and Company; a member of the Basel Institute for Immunology in Basel, Switzerland; and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis. Additionally, he has co-authored more than 70 published, peer-reviewed scientific papers. John completed his Ph.D. in immunology from the University of Chicago and his B.S. in biology from Northern Illinois University.

Basic Compensation

Options Compensation